Raising Contingent Capital: The Case of Cephalon
In early 1997, Cephalon, Inc., a biotechnology firm, purchased 2.5 million capped call options on its own stock, with a potential value of as much as $45 million, in exchange for $9.8 million worth of its common shares. Cephalon's first major drug, Myotrophin, was under review by the U.S. Food...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
2002
|